Anesthetic Nasal Solution Granted FDA Approval

The nasal solution is a local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries.

Officials with the FDA have approved Lannett Company's New Drug Application for cocaine hydrochloride (HCI) nasal solution, 4% (Numbrino).

The nasal solution is a local anesthetic indicated for mucous membranes with diagnostic procedures and surgeries, on or through the naval cavities of adults, according to Lannett.

The NDA submission was supported by a pair of phase 3, placebo-controlled, multicenter studies in several patients, as well as a phase 1 pharmacokinetic study.

REFERENCE

Lannett announces FDA approval of NDA for branded anesthetic product, cocaine hydrochloride nasal solution, 4% [news release]. Philadelphia, PA; Lannett: January 13, 2020. https://lannett.investorroom.com/2020-01-13-Lannett-Announces-FDA-Approval-Of-NDA-For-Branded-Anesthetic-Product-Cocaine-Hydrochloride-Nasal-Solution-4. Accessed January 14, 2020.

Related Videos
Pharmacist helping patient | Image credit: Zamrznuti tonovi - stock.adobe.com
Healthcare technology | Image credit: ipopba | stock.adobe.com
Pharmacist in home infusion environment | Image credit: Satjawat - stock.adobe.com
Gastroenterologist using digital x-ray of human intestine holographic scan projection 3D rendering | Image Credit: sdecoret - stock.adobe.com
Supreme Court | Image credit: steheap - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.